The metastasis-promoting P1597L mutation in PlexinB1 enhances Ras activity

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Metastatic prostate cancer poses a significant health burden, with underlying molecular drivers often unclear.
• Plexins, semaphorin receptors, have varied roles in cancer; a specific mutation (P1597L) in PlexinB1 is linked to prostate cancer metastasis.
• The mechanism by which PlexinB1(P1597L) promotes metastasis remains unknown.

Purpose of the Study:

• To elucidate the molecular mechanism by which the PlexinB1(P1597L) mutation promotes prostate cancer metastasis.
• To investigate the impact of the P1597L mutation on PlexinB1's interaction with small GTPases and its signaling pathways.

Main Methods:

• GST pulldown assays to assess Rap and Ras activity, and protein-protein interactions.
• Immunoblotting for Akt/ERK phosphorylation and cycloheximide treatment for protein stability.
• Monitoring Rho/ROCK activity via MLC2 phosphorylation and cell-collapse assays to evaluate PlexinB1 function.

Main Results:

• The P1597L mutation converts PlexinB1 from a Ras repressor to an activator by inhibiting its RapGAP activity, leading to increased Ras activity.
• The mutation blocks PlexinB1-mediated Rho/ROCK inhibition, preserving Rho signaling and actin stress fibers.
• PlexinB1(P1597L) does not significantly alter interactions with small GTPases or RTKs, nor does it affect Akt/ERK phosphorylation, indicating a specific effect on Rho signaling via Rap/Ras.

Conclusions:

• The P1597L mutation in PlexinB1 drives prostate cancer metastasis by activating Ras signaling through reduced RapGAP activity.
• This study identifies the PlexinB1-Rap-Ras pathway as a critical mediator of prostate cancer progression.
• Targeting the PlexinB1-Rap-Ras pathway offers a potential therapeutic strategy for metastatic prostate cancer.